8-K: Onconetix Announces Successful Clinical Validation of Proclarix Prostate Cancer Test in Danish Cohort

Onconetix's Proclarix test demonstrates strong clinical performance in a Danish cohort, reducing unnecessary biopsies for prostate cancer diagnosis.

Summary

• Onconetix, Inc. announced new clinical data for its Proclarix prostate cancer test presented at the 2025 European Association of Urology (EAU) congress.
• The data demonstrates Proclarix's strong clinical performance in a Danish cohort of patients with suspected prostate cancer.
• Proclarix aims to improve prostate cancer diagnosis by reducing the over-detection of clinically insignificant cancers and unnecessary biopsies.
• In a study of 808 patients, Proclarix was evaluated in prospectively collected samples.
• In a subpopulation of 371 patients with enlarged prostates, a negative Proclarix test resulted in a 5% or less probability of clinically significant cancer, outperforming %fPSA (14%, p=0.028) and the ERSPC risk calculator (20%, p=0.026).
• Proclarix avoided 22% of biopsies while missing the least significant cancers (3 out of 101 patients).
• In an extended population of 654 patients with PSA levels of 2-20 ng/ml, Proclarix showed a sensitivity of 96% and significantly higher specificity compared to %fPSA and ERSPC risk calculator (p<0.001).
• Proclarix is CE-certified under In Vitro Diagnostic Regulation (IVDR) and is indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.
• Onconetix anticipates marketing Proclarix in the U.S. as a lab developed test (LDT) through a license agreement with Labcorp.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for Proclarix, suggesting a promising advancement in prostate cancer diagnostics. The tone is optimistic and highlights the potential benefits of the test.

Positives

• Proclarix demonstrates a high sensitivity (96%) in detecting clinically significant prostate cancer.
• The test has a high negative predictive value (95%), indicating a low probability of missing clinically significant cancer when the test is negative.
• Proclarix can reduce the number of unnecessary biopsies by 22%.
• Proclarix is included in both the European (EAU) and American (AUA) guidelines.
• The company owns ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia (BPH).

Negatives

• The positive predictive value of Proclarix is 32%, indicating a relatively high rate of false positives.
• The test is indicated for a specific population (PSA 2-10 ng/ml, prostate volume >= 35 ml), limiting its applicability to all patients with suspected prostate cancer.

Risks

• The company's ability to commercialize or monetize Proclarix and integrate the assets acquired in the share exchange with Proteomedix is subject to risks.
• Onconetix needs capital to commercially launch Proclarix and maintain adequate working capital.
• The company's ability to attract, hire, and retain skilled personnel is crucial for commercializing and operating its commercial products.
• Failure to obtain and maintain necessary regulatory approvals could hinder the marketing and commercialization of Onconetix's products.
• The company relies on third parties, including manufacturers and logistics companies, which poses a risk.

Future Outlook

Onconetix anticipates marketing Proclarix in the U.S. as a lab developed test (LDT) through its license agreement with Labcorp.

Management Comments

• Ahmed H. Zedan, MD, PhD from Lillebaelt Hospital University Hospital of Southern Denmark said: Proclarix can be safely used to reduce performed biopsies by ruling out patients with clinically insignificant or no prostate cancer and by minimizing the risk of missing clinically significant cancer.

Industry Context

The announcement highlights the ongoing need for improved prostate cancer diagnostics to reduce over-detection and unnecessary biopsies, a common issue with traditional PSA testing. Proclarix aims to address this need by providing a more specific risk assessment tool.

Comparison to Industry Standards

• Proclarix is being compared to %fPSA and the ERSPC risk calculator, which are existing methods for assessing prostate cancer risk.
• The study indicates that Proclarix outperforms these methods in terms of specificity and reducing unnecessary biopsies.
• Companies like Exact Sciences (developing non-invasive cancer diagnostics) and Myriad Genetics (offering prostate cancer risk assessment tests) are competitors in the broader cancer diagnostics market.

Stakeholder Impact

• Shareholders may react positively to the clinical validation of Proclarix.
• Patients may benefit from reduced unnecessary biopsies and improved prostate cancer diagnosis.
• Healthcare providers may have a more accurate tool for assessing prostate cancer risk.

Next Steps

• Onconetix anticipates marketing Proclarix in the U.S. as a lab developed test (LDT) through its license agreement with Labcorp.

Key Dates

Keywords

Proclarix, prostate cancer, diagnostics, biopsy, PSA, Onconetix, clinical validation, EAU, biomarker, ENTADFI